Quest Diagnostics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q4).
- Total institutional ownership fell 0.3 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 96.85% -0.30pp
- Institutions
- 1,350 -5
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 10 sells
| Name | Role | Stake |
|---|---|---|
| James Davis | Chairperson & CEO | 0.11% |
| Catherine Doherty | Executive Vice President of Regional Businesses | 0.07% |
| Michael Prevoznik | General Counsel | 0.04% |
| Michael Deppe | Senior VP, Corporate Controller & Chief Accounting Officer | 0.03% |
| Sam Samad | Chief Financial Officer | 0.03% |
| Timothy Main | Independent Director | 0.02% |
| Vicky Gregg | Independent Director | 0.02% |
| Karthik Kuppusamy | Senior Vice President of Clinical Solutions | 0.01% |
| Patrick Plewman | Senior Vice President of Diagnostic Services | 0.01% |
| Mark Delaney | Chief Commercial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-08 | Patrick Plewman | Senior Vice President of Diagnostic Services | Automatic Disposition | -650 | $257.34 |
| 2026-11-08 | Patrick Plewman | Senior Vice President of Diagnostic Services | Derivative Exercise and Sale | -11,067 | $127.73–257.34 |
| 2026-11-02 | Catherine Doherty | Executive Vice President of Regional Businesses | Other Acquisition | +4,827 | -- |
| 2026-11-02 | Catherine Doherty | Executive Vice President of Regional Businesses | Derivative Exercise and Sale | -22,105 | $121.81–251.24 |
| 2026-11-02 | Mark Delaney | Chief Commercial Officer | Other Acquisition | +2,615 | -- |
| 2026-11-02 | Ramachandran Subu | -- | Other Acquisition | +352 | -- |
| 2026-11-02 | Ramachandran Subu | -- | Other Derivative Acquisition | +1,386 | $248.61 |
| 2026-10-31 | Ramachandran Subu | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-10-25 | Gary Pfeiffer | Independent Director | Automatic Disposition | -1,203 | $243.00 |
| 2026-10-25 | Gary Pfeiffer | Independent Director | Intent to Sell (Form 144) | -1,203 | $243.00 |
| 2026-10-20 | Patrick Plewman | Senior Vice President of Diagnostic Services | Other Acquisition | +41 | $235.94 |
| 2026-10-20 | Timothy Main | Independent Director | Other Acquisition | +18 | $235.94 |
| 2026-10-20 | Robert Carter | Independent Director | Other Acquisition | +10 | $235.93 |
| 2026-10-20 | Vicky Gregg | Independent Director | Other Acquisition | +63 | $235.94 |
| 2026-10-20 | Wright Lassiter | Independent Director | Other Acquisition | +6 | $235.96 |
| 2026-10-20 | Sam Samad | Chief Financial Officer | Other Acquisition | +90 | $235.94 |
| 2026-10-20 | Mark Delaney | Chief Commercial Officer | Other Acquisition | +25 | $235.94 |
| 2026-10-20 | Karthik Kuppusamy | Senior Vice President of Clinical Solutions | Other Acquisition | +33 | $235.94 |
| 2026-09-30 | Timothy Wentworth | Director | Other Derivative Acquisition | +135 | -- |
| 2026-08-31 | James Davis | Chairperson & CEO | Automatic Disposition | -10,000 | $242.72 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.
Quest Diagnostics discussion 0 comments